Boardroom Alpha
Boardroom Alpha
CCRN · Revised Definitive Proxy Statement (DEFR14A) · Filed April 2, 2026

Cross Country Healthcare Inc — Revised Definitive Proxy Statement (DEFR14A)

Form
DEFR14A
Filed
April 2, 2026
Ticker
CCRN
Accession
0000929638-26-001362
About Cross Country Healthcare Inc
Market cap
$423M
1Y TSR
−5.1%
3Y TSR
−22.6%
Board grade
C
Sector
Healthcare
CEO
Kevin Cronin Clark
Last annual meeting: May 11, 2026 · View full Cross Country Healthcare Inc profile →
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
SCHEDULE 14A
 
Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934

(Amendment No. 1)
 



Filed by the Registrant
 
Filed by a Party other than the Registrant
 
Check the appropriate box:
 
Preliminary Proxy Statement
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
Definitive Proxy Statement
Definitive Additional Materials
Soliciting Material Pursuant to §240.14a-12


CROSS COUNTRY HEALTHCARE, INC.
(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
 
Payment of Filing Fee (Check the appropriate box):

No fee required.
Fee paid previously with preliminary materials.
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11.
 

 



 


CROSS COUNTRY HEALTHCARE, INC.
April 2, 2026
 
EXPLANATORY NOTE
 
Cross Country Healthcare, Inc. (the “Company”) filed its Definitive Proxy Statement on Schedule 14A (the “Proxy Statement”) with the Securities and Exchange Commission on March 30, 2026. The Proxy Statement inadvertently contained extraneous language appearing under the section entitled “New Plan Benefits” on pages 87 and 88. The purpose of this proxy statement supplement (the “Supplement”) is to restate the paragraphs that appear under “New Plan Benefits” on pages 87 and 88 of the Proxy Statement in order to remove the extraneous language. The Company’s Board of Directors’ recommendation FOR Proposal 4 is unchanged.
 
Except as specifically revised by this Supplement, this Supplement does not amend, revise, or update any of the other information set forth in the Proxy Statement. This Supplement should be read in conjunction with the Proxy Statement. From and after the date of this Supplement, any references to the “Proxy Statement” are to the Proxy Statement as supplemented hereby. In addition, this Supplement does not reflect events occurring after the date of the Proxy Statement or modify or update disclosures that may have been affected by subsequent events.
 
If you have already submitted your proxy by voting your shares, you do not need to take any action unless you wish to change your vote. Stockholders who have not voted are encouraged to vote as soon as possible.



Amendment to Original Proxy Statement
 
The three paragraphs under “New Plan Benefits” on pages 87 and 88 of the Original Proxy Statement are hereby replaced in their entirety with the following:
 
New Plan Benefits

Future benefits under the Amended Plan generally will be granted at the discretion of the Committee and are therefore not currently determinable.
 
Because future grants under the Amended Plan, if approved, would be subject to the discretion of the Board or the Committee, the amount and terms of future awards to particular participants or groups of participants are not determinable at this time. No awards have been previously granted that are contingent on the approval of the Amended Plan. The closing price of a Share on the Nasdaq as of March 25, 2026 was $9.79.
 



From this filing to the contest

Every contested election, re-scored daily.

Boardroom Alpha forecasts every contested situation and every director up for re-election. 0.88 AUC out-of-sample. Each contested forecast publishes as a long-form note you can hand to your IC.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Cross Country Healthcare Inc (CCRN)

Reference

Frequently asked questions

When did Cross Country Healthcare Inc file this DEFR14A?
Cross Country Healthcare Inc (CCRN) filed this Revised Definitive Proxy Statement (DEFR14A) with the SEC on April 2, 2026. The accession number assigned by EDGAR is 0000929638-26-001362.
What does a DEFR14A disclose?
DEFR14A is a revised definitive proxy statement, filed when a company materially amends its earlier DEF 14A after distribution. Supersedes the prior proxy.
Where can I find Cross Country Healthcare Inc's prior proxy contest filings on EDGAR?
The SEC EDGAR browser lists every DEFR14A Cross Country Healthcare Inc has filed under CIK 1141103, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer